{"DataElement":{"publicId":"5566398","version":"1","preferredName":"Patient Antiemetic Preference Agent Name","preferredDefinition":"Text term to identify a nausea/vomiting medication with which the patient was most satisfied.","longName":"PT_ANTIEMET_PREF_NM","context":"DCI","contextVersion":"1","DataElementConcept":{"publicId":"5566391","version":"1","preferredName":"Patient Choice Antiemetic Preference","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Select from a group._A pharmacological agent that prevents nausea and/or vomiting._The act, fact, or principle of giving advantages to some particular person, object, or course of action over others; designated as more desirable.","longName":"5566389v1.0:2435948v1.0","context":"DCI","contextVersion":"1","ObjectClass":{"publicId":"5566389","version":"1","preferredName":"Patient Choose Antiemetic Agent","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.:Select from a group.:A pharmacological agent that prevents nausea and/or vomiting.","longName":"C16960:C48912:C267","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Choose","conceptCode":"C48912","definition":"Select from a group.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antiemetic Agent","conceptCode":"C267","definition":"A pharmacological agent that prevents nausea and/or vomiting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"40B85430-8E17-4DDD-E053-F662850AB7DF","latestVersionIndicator":"Yes","beginDate":"2016-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-11-07","modifiedBy":"ONEDATA","dateModified":"2016-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2435948","version":"1","preferredName":"Preference","preferredDefinition":"The act, fact, or principle of giving advantages to some particular person, object, or course of action over others.","longName":"C41187","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Preference","conceptCode":"C41187","definition":"The act, fact, or principle of giving advantages to some particular person, object, or course of action over others; designated as more desirable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0781A8FE-4FFD-0C0C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2005-12-09","modifiedBy":"ONEDATA","dateModified":"2005-12-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"40B85430-8E25-4DDD-E053-F662850AB7DF","latestVersionIndicator":"Yes","beginDate":"2016-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-11-07","modifiedBy":"REEVESD","dateModified":"2016-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5566392","version":"1","preferredName":"Antiemetic Agent Name","preferredDefinition":"A name of a designation of the status in the administrative life-cycle of a Context Owner for handling new administered items._A pharmacological agent that prevents nausea and/or vomiting._The words or language units by which a thing is known.","longName":"ANTIEMET_NM","context":"DCI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"40","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Question not answered","valueDescription":"Question Not Answered","ValueMeaning":{"publicId":"5566393","version":"1","preferredName":"Question Not Answered","longName":"5566393","preferredDefinition":"A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).: Indicates that no answer was given.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Question","conceptCode":"C41116","definition":"A sentence of inquiry that asks for a reply; a request for information (e.g., a formal request to a database or search engine).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Not Answered","conceptCode":"C110959","definition":"Indicates that no answer was given.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"40B87ED6-7392-6365-E053-F662850AF15A","latestVersionIndicator":"Yes","beginDate":"2016-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-11-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"40B87ED6-73AB-6365-E053-F662850AF15A","beginDate":"2016-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-11-07","modifiedBy":"ONEDATA","dateModified":"2016-11-07","deletedIndicator":"No"},{"value":"Rolapitant/Ondansetron pill","valueDescription":"Rolapitant Ondansetron Pill","ValueMeaning":{"publicId":"5566395","version":"1","preferredName":"Rolapitant Ondansetron Pill","longName":"5566395v1.00","preferredDefinition":"An orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor) antagonist, with potential antiemetic activity. Upon oral administration, rolapitant competitively binds to and blocks the activity of the NK1-receptor in the central nervous system, thereby inhibiting the binding of the endogenous ligand, substance P (SP). This may prevent both SP-induced emesis and chemotherapy-induced nausea and vomiting (CINV). The interaction of SP with the NK1-receptor plays a key role in the induction of nausea and vomiting caused by emetogenic cancer chemotherapy. Compared to other NK1-receptor antagonists, rolapitant has both a more rapid onset of action and a much longer half-life._A carbazole derivative with antiemetic activity.  As a selective serotonin receptor antagonist, ondansetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. (NCI04)_A solid composed of a small, round object composed of active and/or inert ingredient(s).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rolapitant","conceptCode":"C97952","definition":"An orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor) antagonist, with potential antiemetic activity. Upon oral administration, rolapitant competitively binds to and blocks the activity of the NK1-receptor in the central nervous system, thereby inhibiting the binding of the endogenous ligand, substance P (SP). This may prevent both SP-induced emesis and chemotherapy-induced nausea and vomiting (CINV). The interaction of SP with the NK1-receptor plays a key role in the induction of nausea and vomiting caused by emetogenic cancer chemotherapy. Compared to other NK1-receptor antagonists, rolapitant has both a more rapid onset of action and a much longer half-life.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Ondansetron","conceptCode":"C1119","definition":"A carbazole derivative with antiemetic activity.  As a selective serotonin receptor antagonist, ondansetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pill Dosage Form","conceptCode":"C25394","definition":"A solid composed of a small, round object composed of active and/or inert ingredient(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"40B87ED6-73BA-6365-E053-F662850AF15A","latestVersionIndicator":"Yes","beginDate":"2016-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-11-07","modifiedBy":"KUMMEROA","dateModified":"2023-11-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"40B87ED6-73D3-6365-E053-F662850AF15A","beginDate":"2016-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-11-07","modifiedBy":"ONEDATA","dateModified":"2016-11-07","deletedIndicator":"No"},{"value":"Ondansetron pill","valueDescription":"Ondansetron Pill ","ValueMeaning":{"publicId":"5566396","version":"1","preferredName":"Ondansetron Pill ","longName":"5566396","preferredDefinition":"A carbazole derivative with antiemetic activity.  As a selective serotonin receptor antagonist, ondansetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. (NCI04): A solid composed of a small, round object composed of active and/or inert ingredient(s).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ondansetron","conceptCode":"C1119","definition":"A carbazole derivative with antiemetic activity.  As a selective serotonin receptor antagonist, ondansetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pill Dosage Form","conceptCode":"C25394","definition":"A solid composed of a small, round object composed of active and/or inert ingredient(s).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"40B87ED6-73E0-6365-E053-F662850AF15A","latestVersionIndicator":"Yes","beginDate":"2016-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-11-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"40B87ED6-73F9-6365-E053-F662850AF15A","beginDate":"2016-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-11-07","modifiedBy":"ONEDATA","dateModified":"2016-11-07","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"5485693","version":"1","preferredName":"Antiemetic Agent Name","preferredDefinition":"A pharmacological agent that prevents nausea and/or vomiting.:The words or language units by which a thing is known.","longName":"C267:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antiemetic Agent","conceptCode":"C267","definition":"A pharmacological agent that prevents nausea and/or vomiting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D71EE53-6A73-2E68-E053-F662850A3516","latestVersionIndicator":"Yes","beginDate":"2016-09-26","endDate":null,"createdBy":"ROSSD","dateCreated":"2016-09-26","modifiedBy":"ONEDATA","dateModified":"2016-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"DCI CRF:  Duke Cancer Institute Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"40B87ED6-737B-6365-E053-F662850AF15A","latestVersionIndicator":"Yes","beginDate":"2016-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-11-07","modifiedBy":"REEVESD","dateModified":"2016-11-07","changeDescription":"Permissible values required by DCI CRF.11.7.2016.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2811715","version":"1","longName":"Duke University","context":"NCIP"},{"publicId":"2812724","version":"1","longName":"Duke U New CDEs","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Antiemetic agent","type":"Preferred Question Text","description":"Antiemetic agent","url":null,"context":"DCI"}],"origin":"DCI CRF:  Duke Cancer Institute Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"40B87ED6-7405-6365-E053-F662850AF15A","latestVersionIndicator":"Yes","beginDate":"2016-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-11-07","modifiedBy":"REEVESD","dateModified":"2016-11-07","changeDescription":"Curated to support Duke Cancer Institute protocol.11.7.2016.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}